written by reader Discussion page for Arch Therapeutics (ARTH)

By Lynn Clark, Stock Gumshoe, November 6, 2017

This page is for discussion of Arch Therapeutics (ARTH).

This is a discussion topic or guest posting submitted by a Stock Gumshoe reader. The content has not been edited or reviewed by Stock Gumshoe, and any opinions expressed are those of the author alone.

701
Share your thoughts...

avatar
171 Comment threads
530 Thread replies
0 Followers
 
Most reacted comment
Hottest comment thread
132 Comment authors
GriffinLarry C.drbonzdunnydamenocotek Recent comment authors

This site uses Akismet to reduce spam. Learn how your comment data is processed.

JohnM
Irregular
πŸ‘1978

deleted

kucheka
Irregular
πŸ‘452
kucheka

$ARTH SEC Filing Alert – SC 13G/A: Schedule filed to report acquisition of beneficial ownership of 5% or more of a class of equity securities by passive investors and certain institutions

https://s3.amazonaws.com/content.stockpr.com/sec/0001445866-18-000142/0001445866-18-000142.pdf

satydave
Member
πŸ‘47
satydave

I was searching for Mike and Ana Parker from Arizona (Investors in ARTH) and found this story.
https://www.azcentral.com/story/news/local/karinabland/2016/12/25/how-giving-up-big-diamond-helped-kids-find-their-big-dreams/95691348/

dunnydame
Member
πŸ‘1000
dunnydame

$ARTH ow
For the Parkers wonderful charitable sakes (and we Gummy longs too!) I trust that $ARTH fulfills the promise of its science.
Penny

drbonz
Guest
drbonz

Wow. They sound like wonderful people. And we sure could use some positive JuJu for this stock.

Add a Topic
5971
drbonz
Member
πŸ‘504
drbonz

I just realized that when I post, it is listing me as a β€œGuest” and not an β€œirregular”. My membership is on autopay as far as I know. Travis?

denton
Irregular
πŸ‘398
denton

drbonz – just make sure you are logged in. If not, you will show us as guest…I know because it’s happened to me several times.

v/r
jdd

drbonz
Member
πŸ‘504
drbonz

Thought I did but I must not have been. Now I seem to be back in the world of the Irregulars. Thanks!

finventurer
Irregular
πŸ‘319
finventurer

$ARTH atlas OW

https://ir.archtherapeutics.com/press-releases/detail/503

Arch Therapeutics to Provide Corporate Update at the 30th Annual Roth Conference on March 12, 2018

let’s hope there’s something new and maybe we’ll hear more of 510(k), CE and others too.

drbonz
Member
πŸ‘504
drbonz

With the new posts about ARTH from Cleveland two days ago on the main thread, nothing here concerning them on the ARTH thread?

finventurer
Irregular
πŸ‘319
finventurer

Drbonz, if i understood you correctly: i’m not sure if Cleveland actually posted anything we weren’t familiar with already, so probably nobody bothered to talk (or didn’t know what to add) here about things that have been repeated couple of times before. very thorough post from Cleveland, as usual, and gave us once again a reminder why we decided (or decided not) to invest in $ARTH at the first place. there were also few undisclosed points too that now were served from a bit different perspective. so if there was something in your mind, please feel free to post and… Read More Β»

Add a Topic
4393
Larry C.
Member
πŸ‘122
Larry C.

$ARTH 10xow – Polyganics of the Netherlands has a surgical patch to stop bleeding. β€œIt’s applied like duct-tape on a tube,” CEO Rudy MareelΒ told me about the sealant patch. The device is applied during the operation in tandem with a liver resection or other abdominal surgical procedures. https://labiotech.eu/polyganics-breakthrough-device-fda/.
This may not have the broad application that AC-5 has, but it’s competitive and ARCH failures have given them a head start.

Add a Topic
4393
petervr
Irregular
πŸ‘1537
petervr

$ARTH
Larry – thanks for the “heads up”. Very helpful post.
PetervR

Add a Topic
4393
blackngold63
Irregular
πŸ‘95
blackngold63

$Arth
Agree. Not good news to have any competition out there. Much less one given a fast track FDA approval. Having said that….not sure it is in the same league as the Arch pipeline. But they need to finally leave the gate and get rolling.

Add a Topic
4393
denton
Irregular
πŸ‘398
denton

$Arch Therapeutics Provides Update on 510(k) GlobeNewswireβ€’March 12, 2018 FRAMINGHAM, Mass., March 12, 2018 (GLOBE NEWSWIRE) — Arch Therapeutics, Inc. (ARTH) (“Arch” or the “Company”), developer of liquid, gel and solid hemostatic and wound care devices, today announced that it has utilized the Food and Drug Administration’s (FDA, “the agency”) pre-submission process to submit a proposed development strategy to the FDA to address the agency’s comments on its previous 510(k) submission for its AC5 Topical Gel product. As previously reported, Arch voluntarily withdrew its 510(k) notification for its medical device AC5 Topical Gel from the FDA after receiving comments from… Read More Β»

Add a Topic
4393
tfris
Member
πŸ‘315
tfris

That hurts πŸ™

blackngold63
Irregular
πŸ‘95
blackngold63

I am still a huge believer. I do think it will pan out bigtime. But…I can understand why people have gotten frustrated.

jnsesq48
Irregular
πŸ‘13

I wouldn’t mind sitting on my 10,000 ARTH shares if I hadn’t already lost 4 grand while doing it.

yelpik
Irregular
πŸ‘243
yelpik

I have brought up the fact that other people have patches already and this company is not the first. Doc and eyedoc said it is not the same. The liquid ac5 is better for certain types of bleeds. They thought ac5 was superior. Just FYI

drbonz
Member
πŸ‘504
drbonz

Well, it’s nice to see that it seems like a relatively benign thing that needed to be addressed but it is a big disappointment that we’ll AGAIN have to wait another year or more for commercialization.

yelpik
Irregular
πŸ‘243
yelpik

I also am disappointed about the delay. But I do believe in AC5. I’m more concerned that they will have to do another money raise now. I’m confused if this new FDA application is still only for topical applications or if this could be used internally. Any body else know? Cleveland??

Add a Topic
3022
satydave
Member
πŸ‘47
satydave

The agency requested further evidence that the product does not cause sensitization in humans.
So the FDA is only looking for more evidence that it does not harm humans.

Add a Topic
3022
JohnM
Irregular
πŸ‘1978

The new application is only for external use. But when AC5 is approved, surgeons can use it for internal use if they want to.
ARTH will have to do another capital raise, probably to all the same folks that have put up the money so far.

Add a Topic
4393
wfuiii
Irregular
πŸ‘98

$Arch Ran across this last week but got sidetracked and thought it might be relavent to our discussion. Allergan purchased a private Australian company, Elastagen, for $95M in February. You can read about this here, http://www.elastagen.com/#news. They have several products in development that will fit very well into their Aesthetic portfolio that currently dominates with products like Botox and Juvederm. I also noticed that Elastagen also has also done significant research and development on another product, MeTro, which is a highly elastic protein based surgical sealant that would definitely compete with AC5. I can’t recall this product ever being discussed… Read More Β»

mlent
Member
πŸ‘37
mlent

Not sure I am reading this correctly, but it appears MeTro is not clear and it takes 30-180 seconds. That would make AC5 still the winner.

wfuiii
Irregular
πŸ‘98

AC5 will clearly control bleeding and allow surgeon a clearer field, no contest…but nothing out yet on how long and most likely will not have either the strength or elasticity that MeTro is showing on lungs, vessels and other structures inside the body where pressure control is also a factor. Last thing a surgeon wants is to close an incision only to have bleeding occur days later and have to reopen. The increased time involved still shorter than suturing. I fully admit that these 2 products are apples and oranges…but still both fruits and better than current options. Just a… Read More Β»

Add a Topic
570
satydave
Member
πŸ‘47
satydave

Interesting but not as advanced as AC5. If TN can get FDA agreement for the next phase of human trials, ARCH will be well ahead.

Add a Topic
3022
jking1939
Member
πŸ‘1266
jking1939

$ARTH – Please excuse me if I’m not in the right thread, plus this may be very old news, however, I’m going with the β€œbetter safe than sorry” excuse. β€œArch Therapeutics has filed a pre-submission with the FDA for feedback on its plan that will address FDA comments from its previous AC5 Topical Gel product 510(k) submission, according to a March 12 press release. Arch recently withdrew its 510(k) submission for its medical device after the FDA left comments in the late review process that the company could not completely respond to within the allotted 90-day period. The previous 510(k)… Read More Β»

Add a Topic
4393
Kristilee
Irregular
πŸ‘402
Kristilee

Just came across this. Haven’t seen it posted here. https://www.zacks.com/research/get_news.php?id=6x79pzulaq

richardo8586
Member
πŸ‘510
richardo8586

I’m pretty sure this was previously posted Kristi lie. Not in $ARTH anymore, but cheering for those of you who still are

SoGiAm
Member
πŸ‘11391

$ARTH wow > 10-Q for the quarterly period ended March 31, 2018
https://ir.archtherapeutics.com/all-sec-filings/content/0001144204-18-022685/tv491272_10q.htm Let’s get this party started. πŸ™‚ #Best2ALL! πŸ™‚

Add a Topic
4393
finventurer
Irregular
πŸ‘319
finventurer

$ARTH atlas ow

what to expect of $ARTH, Gr8Full? nothing much happening before the ongoing “small, three-month long, non-invasive human study to provide the additional data to the FDA” is finished? or am i missing something?

Add a Topic
3022
blackngold63
Irregular
πŸ‘95
blackngold63

He’s just being a prick. He left the stock long ago. I guarantee ya he doesn’t even own a share.
I personally don’t think the science has changed. And – It is a low funded start-up biotech. Take your chances obviously.
And I guess we will see who comes out on the top at the end.

Add a Topic
5971
MarshallDillion
Irregular
πŸ‘76
MarshallDillion

Blackngold63. Are you talking about the guy looking back at you in the mirror?

finventurer
Irregular
πŸ‘319
finventurer

i sincerely wish you’d stop talking bad about probably the best contributor this site has ever had. Gr8tFull is on top of so many things most of us can’t even begin to comprehend so i’m afraid you comment is way out of line.

Only you are responsible for your acts, no one else.

Rest of your comment i agree with.

Thomas
Member
πŸ‘50
Thomas

Just another troll

hipockets
Member
πŸ‘1218

I started thinking about re-investing in ARTH after reading the 5/8/18 ARTH press release: “Arch intends to initiate the [sensitization] study in the next few weeks incorporating FDA’s comments and ….. expects to file the 510(k) notification in the third calendar quarter of 2018………..We still expect the trial to cost approximately $100,000 and take about three months.” Doing more research, I found that Arch Therapeutics Initiated a Clinical Trial of AC5 in Europe back in December, 2015 — https://www.fdanews.com/articles/174554-arch-therapeutics-to-initiate-clinical-trial-of-ac5-in-europe . I could find no reference to this trial on the ARTH website. Googling the topic, I found a link to… Read More Β»

finventurer
Irregular
πŸ‘319
finventurer

$ARTH atlas ow

hipockets, please do share your thoughts, if you have any more, regarding ARTH and latest press release πŸ™‚

I thought it was promising, as always, so wasn’t particularly thrilled and will wait for actual actions to be taken by the company and results to be seen. Will not trust plain words anymore.

JohnM
Irregular
πŸ‘1978

finventurer, if ARTH begins the three-month study on skin sensitivity to settle the only remaining outstanding issue for FDA approval, does that count as an “actual action?”

Add a Topic
3022
finventurer
Irregular
πŸ‘319
finventurer

i believe it does, JohnM πŸ™‚

JohnM
Irregular
πŸ‘1978

hipockets, Arch PR’d the results of the clinical trial here:
ir.archtherapeutics.com/press-releases/detail/483/arch-therapeutics-reports-ac5-topical-hemostatic-device
They then PR’d the peer-reviewed publication of the complete results here:
ir.archtherapeutics.com/press-releases/detail/502/dermatologic-surgery-publishes-clinical-data-on-arch

Griffin
Member
πŸ‘3369
Griffin

Thanks for the (no moderatatatater) links. πŸ˜‰

hipockets
Member
πŸ‘1218

$ARTH Thanks, JohnM, for the links. Your info gave me impetus to search for “ARTH CE Approval”. In their 3/12/18 press release, they stated “Arch also expects to file a CE mark in Europe for AC5 in the second half of 2018.” They have been saying they plan to apply for CE Approval every year since 2015, but they never explained why they did not file during those years. I emailed their IR department, and received this reply: “It is not approved in Europe yet but they are looking to gain the CE Mark in due course.” Not very informative… Read More Β»

arch1
Member
πŸ‘7793

Hipockets I cannot disagree. I have long felt that Norchi is not really able to shepherd #ARTH to market.
I hold far too much now and am at loss but still hopeful.
Same story for most of my bio.

JohnM
Irregular
πŸ‘1978

arch1, do you fell Norchi is unable to oversee a three-month human sensitivity trial, or do you think Norchi is not capable of negotiating a distribution deal? Or do you see some other obstacle keeping AC5 from the market?

JohnM
Irregular
πŸ‘1978

hipockts, I think you are being much too negative about ARTH management. (I am very OW.) 1. They did explain why they didn’t file for a CE mark. Their manufacturer told Norchi when they would file, which Norchi repeated to investors. The manufacturer then filled out the forms for a drug filing, which is what they were used to. But AC5 is a device, so they missed their timing. Having said that, I have no idea why it has taken this long for the manufacturer to prepare the correct filing form. I suspect it was unfamiliar to them and required… Read More Β»

Add a Topic
3022
Add a Topic
5971
Add a Topic
229
petervr
Irregular
πŸ‘1537
petervr

John – Many of us have been aboard ARTH for most of its circuitous journey and have heard most of the “stories”. Congratulations on your well thought out comments and observations, supported by a plethora of facts and details. It was a pleasure to read and makes a strong case. Thanks for your efforts to provide it.

Add a Topic
4393
hipockets
Member
πŸ‘1218

$ARTH — JohnM — Thank you for your excellent post. We all have heard about the “Gummy Bounce” – I think we saw a “JohnM Bounce” today! πŸ™‚ Please keep commenting! πŸ™‚

Cleveland
Member
πŸ‘6007

$ARTH

Nice post JohnM $ ARTH up 19 % !!!!!!!!!!!!!!!!!!

I got evicted from Dr. KSS’s forum. I have no idea why. He just canceled me out.

Such is life.